课题基金 / 基金详情

DEVELOPMENTAL CORE

DEVELOPMENTAL CORE
发展核心
批准号:
6936124
负责人:
Susan B Zolla-Pazner
金额:
$61.95万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2010-06-30

项目摘要

项目成果

Susan B Zolla-Pazner的其他基金

相似基金

相关文献

中文摘要
翻译
核心B描述(由申请人提供):CFAR发展核心是一条主要路线 CFAR是纽约大学艾滋病研究的催化剂。发展核心的目标是鼓励新的研究者和创新,并允许对新的研究机会做出快速反应。每年200 000美元的发展资金的大部分用于资助年轻调查人员或艾滋病相关研究领域的新调查人员提出的试点项目。这些奖项是在我们的科学审查委员会对所有提交的申请进行全面评估和讨论后,然后进行无记名投票。最多可向受助人提供5万美元。如果在第一年结束时取得了可喜的成果,如果有充分的理由要求提供额外的福利,如果外部提出了供资申请,委员会有时会同意在第二年再提供50 000美元。这可以提高成功完成项目的能力。另外两类研究可以得到发展基金的支持:对新的研究机会的快速反应,这必须涉及合作努力,以及新技术的开发。
英文摘要
CORE B DESCRIPTION (provided by applicant): The CFAR Developmental Core is a major route by which the CFAR acts as a catalyst for AIDS research at NYU. The goals of the Developmental Core are to encourage new investigators and innovation, and to permit a rapid response to new research opportunities. A major portion of the developmental funds of $200,000 per year is used to fund pilot projects proposed by young investigators or investigators who are new to the area of AIDS-related research. These awards are made after a thorough evaluation and discussion of all submitted applications by our Scientific Review Committee, followed by a secret ballot. An amount of up to $50,000 is awarded to recipients. If promising results have been obtained at the end of the first year, and if a strong case can be made for additional benefit, and if an outside application for funding has been submitted, the Committee has sometimes agreed to provide an additional $50,000 for a second year. This can increase the ability to complete a project successfully. Two additional categories of investigation may be supported by developmental funds: A rapid response to new research opportunities, which must involve a collaborative effort, and the development of new technologies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
Recovery of HIV Monoclonal Antibody Inventory Lost after Hurricane Sandy
Protective Human Monoclonal Antibodies to HIV-1
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
海外基金